FLUDARABINE, CYCLOPHOSPHAMIDE AND LENALIDOMIDE IN RELAPSED/REFRACTORY PATIENTS WITH CLL, PRELIMINARY RESULTS OF THE PHASE1-2 GIMEMA CLL0606 STUDY

被引：0
|
作者：
Mauro, F. R. [1 ]
Carella, A. M. [2 ]
Vignetti, M. [3 ]
Orlando, S. M. [3 ]
Liberati, A. M. [4 ]
Molica, S. [5 ]
Belsito, V. [6 ]
Cortellezzi, A. [7 ]
Zaia, F. [8 ]
Specchia, G. [9 ]
Tosi, P. [10 ]
Campanelli, M. [1 ]
Iannella, E. [1 ]
Trastulli, F. [1 ]
Nanni, M. [1 ]
Marinelli, M. [1 ]
Graziosi, A. [3 ]
Cuneo, A. [11 ]
Guarini, A. [1 ]
Foa, R. [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00185 Rome, Italy
[2] IRCCS San Martino IST, UOC Ematol 1, Genoa, Italy
[3] GIMEMA, Italian Grp Adult Hematol Dis, Rome, Italy
[4] Univ Perugia, Dept Oncohematol, Hosp Santa Maria, Terni, Italy
[5] Azienda Osped Pugliese Ciaccio, Catanzaro, Italy
[6] Umberto I Hosp, Div Hematol Oncol, Nocera Inferiore, Italy
[7] Policlin Fdn, IRCCS Ca Granda Osped Maggiore, Ematol BMT Unit, Milan, Italy
[8] Univ Udine, S Maria Misericordia Hosp, Hematol BMT Unit, I-33100 Udine, Italy
[9] Univ Aldo Moro, UO Ematol Con Trapianto, Bari, Italy
[10] Dept Hematol & Oncol, Hematol Unit, Rimini, Italy
[11] Arcispedale St Anna, Dept Hematol, Ferrara, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P863
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [1] FLUDARABINE, CYCLOPHOSPHAMIDE AND LENALIDOMIDE IN RELAPSED/REFRACTORY PATIENTS WITH CLL, RESULTS OF THE PHASE1-2 GIMEMA STUDY LLC606
    Mauro, F. R.
    Carella, A. M.
    Molica, S.
    Paoloni, F.
    Liberati, A. M.
    Belsito, V.
    Zaja, F.
    Cortellezzi, A.
    Specchia, G.
    Tosi, P.
    Spriano, M.
    Faglioni, L.
    Ferretti, A.
    Trastulli, F.
    Nanni, M.
    Marinelli, M.
    De Propriis, M. S.
    Fazi, P.
    Cuneo, A.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2015, 100 : 79 - 79
  • [2] A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
    Ujjani, Chaitra
    Wang, Hongkun
    Skarbnik, Alan
    Trivedi, Neel
    Ramzi, Pari
    Khan, Nadia
    Cheson, Bruce D.
    BLOOD ADVANCES, 2018, 2 (07) : 762 - 768
  • [3] Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group
    Elter, Thomas
    James, Rojin
    Stilgenbauer, Stephan
    Ritgen, Matthias
    Hallek, Michael
    Engert, Andreas
    BLOOD, 2008, 112 (11) : 1087 - 1087
  • [4] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL
    Wierda, W
    Faderl, S
    O'Brien, S
    Cortes, J
    Ferrajoli, A
    Giles, F
    Andreff, M
    Koller, C
    Kantarjian, H
    Keating, M
    BLOOD, 2004, 104 (11) : 101A - 101A
  • [5] Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL
    Ujjani, Chaitra S.
    Wang, Hongkun
    Skarbnik, Alan P.
    Trivedi, Neel
    Ramzi, Pari
    Khan, Nadia
    Cheson, Bruce D.
    BLOOD, 2017, 130
  • [6] Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study
    Mauro, Francesca Romania
    Armiento, Daniele
    Orlando, Sonia
    Del Giudice, Ilaria
    De Propriis, Maria Stefania
    Nanni, Mauro
    Marinelli, Marilisa
    Matteo, Molica
    Fazi, Paola
    Paoloni, Francesca
    Antonietta, Graziosi
    Collada, Laura
    Guarini, Anna
    Foa, Robin
    BLOOD, 2010, 116 (21) : 592 - 592
  • [7] Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL study group
    Elter, T.
    James, R.
    Wendtner, C. M.
    Stilgenbauer, S.
    Winkler, D.
    Ritgen, M.
    Hallek, M.
    Engert, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [8] Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group
    Elter, T.
    James, R.
    Wendtner, C. M.
    Stilgenbauer, S.
    Winkler, D.
    Ritgen, M.
    Hallek, M.
    Engert, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Safety and efficacy of a modified fludarabine/cyclophosphamide combination in patients with relapsed/refractory CLL and LgNHL.
    Tuscano, J
    Lara, PN
    O'Donnell, RT
    Lauder, IL
    Wun, T
    BLOOD, 2001, 98 (11) : 294B - 294B
  • [10] Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL.
    Wierda, W
    O'Brien, S
    Ferrajoli, A
    Faderl, S
    Kornblau, SM
    Andreef, M
    Koller, C
    Garcia-Manero, G
    Thomas, D
    Kantarjian, H
    Keating, M
    BLOOD, 2003, 102 (11) : 360B - 360B
12345